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Objective: Vascular permeability and inflammatory demyelination are intimately linked in the brain, but what is their
temporal relationship? We aimed to determine the radiological correlates of the earliest tissue changes accompany-
ing demyelination in a primate model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE)
in the common marmoset.
Methods: By 7T magnetic resonance imaging (MRI), T1 maps, proton density, and T2-weighted images were
acquired before and after EAE induction in 5 marmosets (every other week before lesions appeared, weekly there-
after). From scans before and after intravenous injection of contrast material, we measured the evolution of lesional
blood–brain barrier (BBB) permeability, comparing in vivo MRI to postmortem tissue examination.
Results: On average, BBB permeability increased 3.5-fold (p< 0.0001) over the 4 weeks prior to lesion appearance. Per-
meability gradually decreased after lesion appearance, with attendant changes in the distribution of inflammatory cells
(predominantly macrophages and microglia) and demyelination. On tissue analysis, we also identified small perivascular
foci of microglia and T cells without blood-derived macrophages or demyelination. These foci had no visible MRI corre-
lates, although permeability within the foci, but not outside, increased in the weeks before the animals died (p< 0.0001).
Interpretation: This study provides compelling evidence that in marmoset EAE, which forms lesions strongly resem-
bling those of MS, early changes in vascular permeability are associated with perivascular inflammatory cuffing and
parenchymal microglial activation but precede the arrival of blood-derived monocytes that accompany demyelin-
ation. Prospective detection of transient permeability changes could afford an opportunity for early intervention to
forestall tissue damage in newly forming lesions.
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Multiple sclerosis (MS) is pathologically characterizedby focal inflammatory and demyelinated lesions in
the brain and spinal cord.1 Longitudinal, serial magnetic
resonance imaging (MRI) can follow in vivo the develop-
ment of new brain lesions over time. MRI techniques can
detect pathological changes in white matter areas of subse-
quent lesion formation up to several weeks before lesions
appear on conventional MRI,2–8 possibly before the onset
of demyelination. Blood–brain barrier (BBB) permeability
in cerebral inflammatory demyelination allows serum pro-
teins and inflammatory cells to enter the parenchyma,9
but whether this heralds or follows demyelination remains
unknown. In vivo, this process can be visualized through
MRI signal changes associated with leakage of paramag-
netic, gadolinium-based contrast agents injected intrave-
nously.10 The presence of contrast enhancement within an
MS lesion usually indicates that the lesion has developed
recently—typically within the past 1 to 2 months.
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In human studies, the pathological correlates of
developing MS lesions are exceedingly difficult to eluci-
date, as lesions are rarely fatal, and areas of future lesion
development are not likely to be included or recognized
in biopsy samples. Autopsy studies describe areas of pos-
sible (but not proven) future lesion formation as small
foci of inflammatory cells, mostly activated microglia,
without established demyelination.11–13 Microglial activa-
tion in these areas has been associated with fibrinogen
leakage related to BBB disruption.14,15 However, due to
their small size, relatively little inflammation, and lack of
demyelination, these inflammatory foci are not directly
visible on in vivo conventional MRI.
With this background, we aimed to test whether pre-
lesional inflammatory changes can be detected by serial 7T
MRI in an animal model of MS that bears strong immu-
nological and pathological similarities with the human dis-
ease: relapsing–remitting experimental autoimmune
encephalomyelitis (EAE) in the common marmoset.16 The
experimental paradigm included imaging at baseline and
frequently after disease induction and focused on detecting
lesions as well as local BBB permeability changes over
time. By comparing imaging data with postmortem histo-
pathology, we determined the immunopathological under-
pinnings of altered BBB permeability as a function of
lesion age. Similarly, we correlated pathological areas
resembling putative areas of future lesion development in
human MS with in vivo MRI findings.
Materials and Methods
EAE Induction
Five adult common marmosets (Callithrix jacchus; 2.6–5 years
old, mean age5 4 years; 4 males) were used for EAE experi-
ments. Data from healthy animals derive from the baseline
studies of these animals. All marmosets were housed at NIH
Intramural Research Program (Public Health Service Assurance
#A4149-01) facilities as previously described,17 in accordance
with the standards of the American Association for Accredita-
tion of Laboratory Animal Care and the National Institute of
Neurological Disorders and Stroke’s Animal Care and Use
Committee, which approved our experimental protocol. Mar-
mosets were immunized with 0.2mg of fresh-frozen human
white matter homogenate (WMH) as previously described.17
Clinical Evaluation
A scoring scale gauged the severity of clinical disease:18 05 no
clinical signs; 0.55 apathy, altered walking pattern without
ataxia; 15 lethargy, anorexia, weight loss; 25 ataxia, sensory
loss; 2.255monoparesis; 2.55 paraparesis; 35 paraplegia or
hemiplegia; 45 quadriplegia; 55 spontaneous death due to
EAE. Animals were assessed 33 weekly by a trained observer
and once weekly by a physician. The experiment was termi-
nated, following local ethical guidelines, at disease score 3.
In Vivo MRI Measurements and Contrast
Administration
Animal preparation for in vivo MRI experiments was conducted
as previously described.17 In vivo imaging was performed in a
7T/30cm Avance AVIII MRI scanner (Bruker BioSpin, Biller-
ica, MA, USA) equipped with a 15cm gradient set (Resonance
Research, Billerica, MA, USA). A custom-built birdcage volume
coil (inner diameter5 10.2 cm) was used for radiofrequency
(RF) excitation. MRI signal collection was performed using a
custom-made 5-channel surface coil array anatomically con-
forming to the marmoset head. Animals were scanned at base-
line, every other week after immunization, and weekly after
discrete lesions were observed. All scans were acquired with
data covering the whole brain.
We used, in the same session, data from 4 MRI sequences:
2-dimensional (2D) coronal high-resolution T1-weighted modi-
fied driven equilibrium Fourier transform (MDEFT; nominal in-
plane resolution5 0.15 3 0.15 mm, slice thickness [ST]5 0.3
mm, inversion time [TI]5 1,200 milliseconds, repetition time
[TR]5 10.5 milliseconds, echo time [TE]5 3.4 milliseconds,
flip angle [FA]5 12, acquisition time [AT]5 25 minutes), 2D
coronal proton density (PD)-weighted spin-echo (nominal in-
plane resolution5 0.15 3 0.15 mm, ST5 0.6 mm, TR5 1,700
milliseconds, TE5 17 milliseconds, FA5 90, AT5 7 minutes),
2D coronal proton density T2-weighted rapid acquisition of refo-
cused echoes (RARE; nominal in-plane resolution5 0.15 3 0.15
mm, ST5 0.6 mm, TR5 1,200 milliseconds, TE5 72 millisec-
onds, FA5 90, AT5 6 minutes, echo train length5 8), and 2D
coronal MDEFT (nominal in-plane resolution5 0.6 3 0.6 mm,
ST5 0.6 mm, TR5 4,500 milliseconds, FA5 9; AT5 3.5
minutes) acquired 33 with different TI (150, 1,200, and 4,000
milliseconds), both before and 20 minutes after the administra-
tion of a bolus of gadopentetate (Bayer, Leverkusen, Germany).
Each monkey received 0.3mmol/kg gadopentetate over 3
minutes.
Ex Vivo MRI Measurements
At the conclusion of the experiment, animals were transcardially
perfused with cold 4% paraformaldehyde, and the whole brain
was removed and placed in 10% neutral buffered formalin.
Brains were placed in a plastic tube filled with nonmagnetic oil
(Fomblin; Solvay, Brussels, Belgium), and postmortem MRI
was obtained in the same magnet using a 38 mm inner diame-
ter birdcage volume RF coil. For each animal, whole brain 3D
T2*-weighted multigradient echo (nominal resolution5 0.1
mm isotropic, TR5 57 milliseconds, shortest TE5 3.6 milli-
seconds, echo spacing5 4 milliseconds, number of echoes5 10,
FA5 90, AT5 1.1 hour, number of excitations5 8) and 2D
T2-weighted RARE (nominal in-plane resolution5 0.1 3 0.1
mm, ST5 0.3 mm, TR5 1,200 milliseconds, TE5 12 milli-
seconds, AT5 50 minutes, number of excitations5 8) were
acquired.
Image Postprocessing
Data were analyzed using algorithms implemented in MIPAV
(NIH, Bethesda, MD, USA), JIST (nitrc.org/projects/jist),
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MATLAB (MathWorks, Natick, MA, USA), and FSL (FMRIB,
Oxford, UK). At each time point, the high-resolution T1-
MDEFT scan was rigidly registered to the baseline T1-MDEFT
scan. Pre- and postcontrast T1 maps were obtained from the
variable-TI 2D MDEFT images using an algorithm imple-
mented in MIPAV.19 The TI5 1,200-milliseconds 2D MDEFT
image, which has T1 weighting, was affine-registered (FSL
FLIRT) to the baseline-registered T1-MDEFT, and the trans-
formation matrix was applied to the T1 map itself. We created
maps of the contrast-induced change in the following longitudi-
nal relaxation map: DR15 1/T1post2 1/T1pre.
For each animal, white matter regions of interest (ROIs)
were delineated manually on coronal slices from the baseline
T1-MDEFT scan using MIPAV tools. Lesion detection was per-
formed on the arithmetic average between PD and T2 scans
(denoted as T2PD), because this image provided excellent
lesion-to-white matter contrast. At each time point, lesion ROIs
were delineated manually on the unregistered T2PD and con-
verted to a binary mask, yielding what we term a time-varying
lesion mask. Then the transformation matrix used for the regis-
tration of the T2PD to the baseline T1-MDEFT scan was also
applied to the time-varying lesion mask. We merged all time
points’ time-varying lesion masks to obtain a final lesion mask.
Subtracting the final lesion mask from the baseline white matter
mask created a normal-appearing white matter (NAWM) mask.
On the final lesion mask, each lesion was labeled with a
unique, lesion-specific identification number. For each lesion i,
we denoted tlesion,i5 0 as the time of its first appearance on the
in vivo T2PD.
Estimation of BBB Permeability
Intravenous injection of low–molecular-weight contrast agents,
such as gadopentetate, allows detection of areas of impaired
BBB permeability, as such agents do not normally leak from
vessels into the interstitial space. The passage of gadopentetate
from vessels into the brain parenchyma changes the magnetic
properties of the tissue itself, shortening its longitudinal relaxa-
tion time (T1). T1 mapping allows quantitative estimation of
the T1 within each unit of brain tissue volume, termed a voxel.
The average T1 within all voxels contained in an ROI can thus
be estimated. In this study, T1 maps were acquired prior to
(T1pre) and 20 minutes after (T1post) intravenous gadopentetate
injection and were used to calculate the change in the longitu-
dinal relaxation rate, DR15 1/T1post2 1/T1pre, an estimate of
BBB permeability in lesion areas and NAWM.
In each voxel, DR1 is proportional to the concentration
of the contrast agent in the corresponding area of white mat-
ter20: DR1(t1)5 r1C(t1), where t1 denotes the time since con-
trast injection (20 minutes in our experiments) and r1 the
relaxivity of gadopentetate at 7T (4.17 mM21/s21). It is impor-
tant to realize that intravoxel contrast agent may be found both
at high concentration within blood vessels (which is normal)
and in lower concentration within the extracellular space
(abnormal). Thus, any increase in DR1 may be due either to
permeability or to vascular enlargement. Although tracer kinetic
modeling techniques are typically used to distinguish these pos-
sibilities, in our data such models were difficult to fit and the
results hard to interpret. Nevertheless, the time course of DR1
changes within lesion areas reported in this article, together
with the results of simulations (not described here) that demon-
strated that DR1 changes of the magnitude reported here would
be difficult to explain on the basis of vascular enlargement, sug-
gests that permeability changes are the most likely explanation
for our findings.
Immunohistochemistry and Histological Staining
Brain tissues examined for this study were embedded in paraf-
fin, sectioned at 5 mm, and stained using hematoxylin and
eosin (H&E). To characterize the changes present by immuno-
histochemistry, immunoperoxidase staining for glial fibrillary
acidic protein (GFAP), ionized calcium binding adapter
molecule-1 (Iba1), calprotectin-monocyte L1 protein Ab-1
(MRP14; also known as MAC387), 20,30-cyclic nucleotide 30-
phosphodiesterase (CNPase), CD3, and CD20 were used.
GFAP marks astrocytes. Iba1 is a calcium-binding protein that
is microglia/macrophage-specific21 and does not cross-react with
neurons and astrocytes.22 MRP14/MAC387, also known as cal-
protectin, is a heterocomplex that is expressed on monocytes
and macrophages that have recently infiltrated in early inflam-
mation.23,24 CNPase is expressed in high levels by oligodendro-
cytes and myelin. CD3 is used as a pan–T-cell marker, whereas
CD20 is used to identify B cells. Special stains, including Biel-
schowsky’s method for neurofibrils and Luxol fast blue (LFB)
for myelin, were also performed.
Immunohistochemical staining for CD3 was performed
using the automated Discovery Ultra platform system (Ventana
Medical Systems, Tucson, AZ, USA) employing antihuman
CD3 primary antibody (Dako, Carpinteria, CA, USA; polyclo-
nal) and biotinylated goat antirabbit secondary antibody (Vector
Laboratories, Burlingame, CA, USA). For all other immunohis-
tochemical stains, formalin-fixed, paraffin-embedded sections of
brain and spinal cord were deparaffinized, rehydrated, and sub-
sequently blocked with 3% hydrogen peroxide in phosphate-
buffered saline. Pretreatment for MRP14 was performed using
Protease K for 5 minutes at room temperature. Iba1, CNPase,
and CD20 pretreatment involved microwaving for 20 minutes
in 0.01 citrate buffer, followed by 20 minutes of cooling.
GFAP did not require pretreatment.
Following pretreatment, an avidin–biotin block (Invitro-
gen, Frederick, MD, USA) and then a Dako protein block (10
minutes) were conducted on all sections. A wash of Tris-
buffered saline followed each step. Sections were incubated with
antihuman GFAP (Thermo Scientific, Waltham, MA, USA;
monoclonal; 1:1,600; overnight at 4C), CNPase Ab-1 (Neo-
markers, Fremont, CA, USA; monoclonal; clone 11-5B; 1:200;
1 hour at room temperature), calprotectin–monocyte L1 pro-
tein Ab-1/MRP14 (Lab Vision, Fremont, CA, USA; monoclo-
nal; clone MAC387; 1:200; 30 minutes at room temperature),
Iba1 (Wako Pure Chemical Industries, Osaka, Japan; polyclo-
nal; 1:1,000; 30 minutes at room temperature), and CD20
(monoclonal; 1:179; overnight at 4C). Slides were then incu-
bated with secondary antibody: biotinylated horse antimouse
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(Vector Laboratories; 1:200; 30 minutes at room temperature)
for GFAP, CNPase, MRP14/MAC387, and CD20, and biotin-
ylated goat antirabbit (Vector Laboratories; 1:200; 30 minutes
at room temperature) for Iba1. This was followed by 30-
minute incubation at room temperature with Vectastain ABC
Elite (Vector Laboratories) for GFAP, Iba1, CNPase, and
MRP14/MAC387 and Vectastain ABC Standard (Vector Labo-
ratories) for CD20. Antigen–antibody complex formation was
detected using diaminobenzidine (Dako) and counterstained
with Mayer’s hematoxylin. Irrelevant, isotype-matched primary
antibodies were used in place of the test antibody as negative
controls in all immunohistochemical studies. Positive control
tissues consisted of rhesus macaque cerebrum (GFAP, CNPase),
spleen (Iba1, MRP14/MAC387), and axillary lymph node
(CD3, CD20).
Histopathological analysis was performed on the brains of
the following animals: WMH2, WMH3, WMH4, and
WMH5. A total of 2 brain regions (each brain region consist-
ing of consecutive coronal sections of the same brain area) for
WMH2, WMH4, and WMH5, and 1 for WMH3, were char-
acterized with immunohistochemistry and special stains.
MRI–Histopathology Correlation
To achieve a correlation between MRI and histopathology,
paraffin-embedded brain tissues were sectioned using a custom-
built cutting box that yielded histopathological brain sections
with a similar orientation to that adopted for MRI acquisition.
H&E-stained sections were first visually matched with the ex
vivo MRI images using anatomical landmarks (Fig 1). In vivo
longitudinal T2PD images were then visually matched to the ex
vivo MRI and H&E sections. The other special stains and
immunohistochemistry sections had been serially cut with
respect to the H&E sections and were thus naturally coregis-
tered. The age (in weeks) of each lesion that was visible on
postmortem sections was established by analyzing the time
interval between its first appearance on in vivo T2PD and the
day the experiment was terminated.
Lesions
In this report, the term lesion is used to describe areas where
demyelination is present. On T2PD MRI, those areas corre-
sponded to abnormal, visually detectable, hyperintense signal in
the cerebral white matter. Abnormalities without clear T2PD
MRI correlates are denoted foci, a term that in this report sub-
sumes alterations in permeability, which we denote prelesional
changes in DR1, and their apparent histopathological correlates,
which we denote nondemyelinated inflammatory nodules. In our
animals, cortical lesions were rarely seen on MRI and not
examined on pathology, despite prior reports of cortical lesions
in marmoset EAE induced with a different antigen, recombi-
nant human myelin oligodendrocyte glycoprotein.25–27 For
lesions that traversed both white and gray matter, only the
white matter portion was included in the present analysis.
Nondemyelinated Inflammatory Nodules
Foci not visible on in vivo T2PD MRI, but apparent on
matched histological sections as collections of Iba11 cells and
variable numbers of perivascular lymphocytes, were classified as
nondemyelinated inflammatory nodules. Corresponding ROIs
were drawn on the visually matched in vivo MRI and then
applied longitudinally to the DR1 maps. For each inflammatory
nodule, a control ROI (maintaining size and, to the extent pos-
sible, brain location) was placed in the NAWM.
Statistics
For the analysis of changes in lesion DR1 over time, we used
repeated-measures analysis of variance (ANOVA). The time
from a lesion’s first appearance on MRI (tlesion,i) was considered
as a categorical variable with heterogeneous compound symme-
try as covariance structure. Animal number was considered as a
random variable and lesion volume and lesion DR1 at baseline
as covariates. The Tukey method was applied to pairwise com-
parison among time points. To evaluate DR1 changes within
the NAWM over time, we used a random coefficient model
with time treated as continuous. For the combined analysis of
DR1 in inflammatory nodules, lesions (only those belonging to
animals having inflammatory nodules), and control areas
(NAWM), a random coefficient model was applied, including
group (inflammatory nodule vs lesion vs NAWM), weeks from
a lesion’s first appearance on MRI (tlesion,i), and their interac-
tion. In addition, repeated-measures ANOVA was used to esti-
mate DR1 mean and standard error at each time point, with
time considered as a categorical variable. For this analysis, we
assumed that the last week before the end of the experiment
FIGURE 1: Matched hematoxylin and eosin section (left) and ex-vivo T2* magnetic resonance imaging slice (right) from WMH3.
[Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
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coincided with tlesion521 for the inflammatory nodules. The
SAS (SAS Institute, Cary, NC) procedure MIXED was used for
the above analyses. To adjust for multiple tests, p5 0.01 was
used as the significance level.
For all of the above analyses, to reduce the impact of partial
volume averaging on our results, ROIs with size< 10 pixels
(0.06mm3) were excluded, as were lesions directly bordering the
ventricles and/or large cerebral veins. Vicinity to the ventricles
might also impair lesion identification due to the high MRI signal
of cerebrospinal fluid. Vicinity to larger cerebral veins might affect
lesion DR1 due to the presence of intravascular contrast agent.
Results
All Animals Developed Clinical and Radiological
Disease
EAE was induced in 5 outbred common marmosets (C.
jacchus) with human WMH and complete Freund adju-
vant.17 All immunized animals developed EAE. Clinical
and radiological characteristics of the disease are summar-
ized in Table 1. The time interval between immunization
and the appearance of the first cerebral white matter
lesion on MRI varied considerably, ranging from 2 to 16
(mean5 7) weeks. In 4 animals (WMH1, WMH2,
WMH4, and WMH5), the appearance of the first lesion
preceded the onset of clinical symptoms; in WMH3, the
2 events occurred at the same time.
Lesion development was an ongoing process once it
started. For each animal, the total lesion volume per
week is summarized in Fig 2, which demonstrates hetero-
geneity in the time of incidence and rate of progression
of MRI-defined brain lesions in marmoset EAE. WMH1
developed minor clinical signs (visual impairment and
sensory loss), and in vivo brain MRI demonstrated 351
small, disseminated lesions. WMH2 developed mild clin-
ical signs suggestive of sensory dysfunction 11 weeks after
immunization, which completely resolved. It then pre-
sented acute paraplegia 28 weeks after immunization,
leading to termination of the experiment. MRI showed
38 medium-sized white matter lesions. WMH3 devel-
oped monoparesis of a lower limb 16 weeks after immu-
nization. The experiment was terminated 3 weeks later
due to a respiratory complication related to anesthesia.
MRI showed 6 medium-to-large white matter lesions.
WMH4 did not show clinical symptoms until 7 weeks
after immunization, when the experiment was terminated
due to acute hemiplegia. Radiologically, this animal pre-
sented 42 medium-sized white matter lesions. WMH5
showed recurrent intentional tremor at week 5, which
completely resolved within 1 week. The experiment was
terminated 9 weeks after immunization due to severe
FIGURE 2: Cumulative volume of brain white matter lesions
over time in marmoset experimental autoimmune encepha-
lomyelitis induced with human white matter homogenate.
[Color figure can be viewed in the online issue, which is
available at www.annalsofneurology.org.]
TABLE 1. Clinical and Radiological Disease Characteristics in Marmosets with Experimental Autoimmune
Encephalomyelitis Induced by Injection of Human WMH
Animal Age,
years
Sex Time to
Lesion
Development,
weeks
Time to
Onset of
Clinical
Symptoms,
weeks
Time to
10% Weight
Loss,
weeks
Total Lesion
Volume at
Terminal
MRI, mm3
Total MRI-
Visible
Lesions,
No.
Experiment
Duration,
weeks
WMH1 4.5 M 2 4 3 78.8 351 7
WMH2 2.6 M 8 11 9 19.2 38 28
WMH3 3.3 F 16 16 19 14.5 6 19
WMH4 4.5 M 2 7 7 39.0 42 7
WMH5 5.0 M 7 9 6 2.8 21 9
Time to lesion development (as assessed by repeated MRI), time to onset of clinical symptoms, time to 10% body weight loss, and time
to perfusion (termination of the experiment) are expressed in weeks. Time to onset of clinical symptoms is the time between immuniza-
tion and a clinical score 2, indicating ataxia, visual dysfunction, weakness, and/or sensory loss. The total white matter lesion volume at
the time of the final scan (Terminal MRI) and the cumulative number of MRI-visible brain white matter lesions are also reported.
F5 female; M5male; MRI5magnetic resonance imaging; WMH5white matter homogenate.
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weight loss. In vivo brain MRI showed 21 medium–large
white matter lesions.
BBB Permeability Changes Preceding Lesion
Appearance on MRI
In all animals, brain MRI was performed every 2 weeks
after immunization and weekly after the first white mat-
ter lesion appeared on the T2PD scan. Fig 3A shows the
time course of prelesional changes in DR1 (our measure
of BBB permeability); tlesion5 0 denotes the time of
lesion appearance on T2PD in all 189 white matter
lesions. These data demonstrate that DR1 is roughly sta-
ble prior to 4 weeks before lesion appearance. The statis-
tical analysis focused on changes occurring between 6
weeks before lesion appearance and the time of lesion
appearance (see Fig 3B). There were no week-to-week
changes in DR1 prior to week 24. However, DR1 increased
between weeks 24 and 23 (p< 0.0001), weeks 23 and
21 (p< 0.005), and weeks 21 and 0 (p< 0.0001). By
contrast, considering both pre- and post-immunization
time points, DR1 in NAWM did not change over time
(p5 0.77). These results suggest increasing local BBB
permeability in areas of future lesion development.
Nondemyelinated Inflammatory Nodules and
Focal BBB Permeability Changes
In 3 animals, histopathological analysis of brain sections
showed small inflammatory foci that were not visible, or
barely visible, on in vivo T2PD, including the scan per-
formed just before termination of the experiment (termi-
nal MRI in Fig 4A). These areas appeared as small
clusters of perivascular and parenchymal Iba11 activated
microglia and macrophages21 associated with variable
numbers of perivascular lymphocytes but no demyelin-
ation. Such clusters were denoted nondemyelinated
inflammatory nodules (see Fig 4B). For each inflammatory
nodule, distance from the closest MRI-visible lesion, total
number of blood-derived MRP141 early activated mac-
rophages present in the nodule area, and presence/
absence of focal abnormal signal on high-resolution ex
vivo MRI (100 lm isotropic resolution) are presented in
Table 2. Staining of myelin with LFB showed no demye-
lination in any of the 9 inflammatory nodules we ana-
lyzed.28 MRP141 macrophages were completely absent
in 4 of the 9 nodules (44%); in the others, there were
very few (range5 1–5) in the perivascular space and/or
parenchyma. T cells were present within the perivascular
space and rarely in the parenchyma. GFAP-expressing
reactive astrocytes enveloped vessels, and their thickened
processes extended into the adjacent parenchyma, sug-
gesting endothelial activation29 and response to injury.
To determine whether these inflammatory nodules
represented the histopathological correlate of the prele-
sional DR1 changes detected by MRI, ROIs were placed
in the corresponding location on in vivo scans. DR1 was
recorded at the final time point and during each of the 4
previous weeks. For comparison, corresponding ROI
were placed in the NAWM, maintaining size and, to the
extent possible, brain location.
DR1 increased within inflammatory nodules over
the 4 weeks prior to experiment termination, as shown
in Fig 4C. As this pattern was similar to that observed
prior to formation of MRI-visible lesions, the slopes of
the rise in DR1 were compared, treating the final time
point for inflammatory nodules as 1 week prior to lesion
FIGURE 3: Focal blood–brain barrier permeability, estimated
as the change in longitudinal relaxation rate following intrave-
nous administration of gadolinium-based contrast dye (DR1),
increases before the appearance of brain white matter lesions
on magnetic resonance imaging. (A) Normal appearing (extra-
lesional) white matter (square symbols) and lesion (round sym-
bols) permeability changes over time across all marmosets
with experimental autoimmune encephalomyelitis. tlesion50
denotes the time of lesion appearance on imaging, measured
in weeks. Lesion DR1 remains stable prior to 4 weeks before
lesion appearance (tlesion524). After tlesion524, DR1
increases in lesion areas, peaking at the time of lesion
appearance (tlesion50), and decreases over the 4 weeks
thereafter. Permeability in the normal-appearing white matter
is stable over time (p50.77). (B) Average changes to perme-
ability within the lesion area over time (*p<0.001,
**p<0.0001). Error bars represent standard errors of the
mean. [Color figure can be viewed in the online issue, which
is available at www.annalsofneurology.org.]
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appearance on T2PD (ie, tlesion521). The slope,
expressed in s21/wk, was nonzero for both inflammatory
nodules and lesions: 0.0083 for inflammatory nodules
(p5 0.006) and 0.0062 for lesions (p< 0.0001). There
was no difference between inflammatory-nodule and
lesion slopes (p5 0.39), and there was no trend in
NAWM (p5 0.58). This suggests that DR1 within the
inflammatory nodules during the 4 weeks before experi-
ment termination behaves very similarly to DR1 in areas
that eventually become focal demyelinated lesions.
Lesion Histopathology and BBB Permeability as
a Function of Lesion Age
In MS, the histopathological features and pattern of BBB
permeability change considerably during the lifetime of a
lesion.22,30 We determined how lesion histopathology
and BBB permeability evolved after lesion appearance on
T2PD. For 31 analyzed lesions in 4 animals, lesion age
was defined as the interval between the time of the
lesion’s first appearance on T2PD and experiment termi-
nation. Lesions present on histopathology were classified
as acute if younger than 1 week (n5 5), subacute if
between 1 and 5 weeks (n5 14), and late subacute if
between 5 and 9 weeks (n5 12; Table 3).
Acute Lesions
Acute lesions (<1 week old) corresponded to areas of
discrete hyperintensity on T2PD MRI (Fig 5). BBB per-
meability within the lesion was maximal at this stage of
lesion formation (tlesion5 0; see Fig 3B). On histopathol-
ogy, acute lesions surrounded a central inflamed blood
vessel. CD31 lymphocytes (T cells) and Iba11 activated
microglia and macrophages composed the perivascular
cuff. CD201 lymphocytes (B cells) and blood-derived
MRP141 early activated macrophages were also observed
perivascularly, although less frequently. The parenchyma
adjacent to the central vessel contained a large number of
Iba11 and MRP141 cells. Many of the MRP141 cells
FIGURE 4.
FIGURE 4: Nondemyelinated inflammatory nodules are asso-
ciated with increasing blood–brain barrier permeability over
time. (A) Matched T2PD terminal magnetic resonance imag-
ing (MRI) scan and ionized calcium binding adapter
molecule-1 (Iba1) coronal section of the brain (WMH4). The
representative inflammatory nodule appears as a small clus-
ter of Iba11 cells (black arrow) that is not visible, or barely
visible, on the matched in vivo MRI (white arrow). Red
boxes indicate magnified views. Scale bars5300 lm. (B)
Histological characterization of the inflammatory nodule
shown in A. Only 1 MRP141 blood-derived early activated
macrophage (with MRP14 reaction measured as moderate)
is present within the perivascular space, but not within the
parenchyma. Iba11 activated microglia and macrophages
are present in the perivascular space and parenchyma.
GFAP1 astrocytes are present within the parenchyma and in
contact with the central vessel. CD31 lymphocytes (T cells)
are located at the edge of the vessel wall and in the peri-
vascular space but do not extend into the parenchyma.
CD201 cells were detected in the perivascular space (not
shown). CNPase (an oligodendrocyte and myelin marker) is
normally expressed, and Luxol fast blue (LFB), which stains
myelin in blue, shows no demyelination. Scale bars550lm.
(C) Nondemyelinated inflammatory nodules (red), lesions
(purple), and normal-appearing white matter (blue) perme-
ability, estimated as DR1. For lesions, DR1 is shown over the
4 weeks prior to lesion appearance on T2PD MRI. For the
inflammatory nodules, we assumed that the week the
experiment was terminated coincided with the week pre-
ceding lesion appearance. There was no difference between
slopes of the permeability curves for inflammatory nodules
and lesions (p50.39); however, unlike normal-appearing
white matter, permeability within inflammatory nodules and
lesions was significantly >0 (p<0.001). Error bars represent
standard error of the mean.
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demonstrated ameboid morphology, consistent with an
activated phenotype.23 Parenchymal T and B cells were
rare. Astrocytes with high GFAP expression, cytoplasmic
enlargement, and thick, prominent processes, all of which
suggest activation, were found throughout the lesion
parenchyma, particularly adjacent to vessels. Loss of LFB
staining throughout the lesion indicated demyelination.
Reduced CNPase expression paralleled the decreased LFB
staining, suggesting reduced oligodendrocyte and myelin
density (see Fig 4B).31 Bielschowsky’s silver stain showed
that axons are disrupted and separated by inflammatory
cells, unlike axons outside lesions (see Fig 4B). These histo-
pathological features were present in all acute lesions and
indicate that, within lesions, demyelination begins near the
perivascular cuff. All demyelinated lesions observed on tis-
sue sections were visible on in vivo T2PD MRI.
Subacute Lesions
MRI-dated lesions between 1 and 5 weeks old were clas-
sified as subacute. These appeared on T2PD as discrete
areas of abnormal hyperintensity. The size of these lesions
typically increased over time on longitudinal MRI (Fig
6). Sometimes a central vessel, appearing as a linear
hypointensity on T2PD, was visible in the center of the
lesion. Between 1 and 2 weeks after lesion appearance,
BBB permeability was significantly lower than in acute
lesions <1 week old. Between 2 and 4 weeks after lesion
appearance, however, there were no significant permeabil-
ity changes (see Fig 3B).
In subacute lesions, especially those 3 to 5 weeks
old, there was marked demyelination at the center and
slightly less demyelination at the margin. Similarly,
CNPase expression in oligodendrocytes and myelin was
TABLE 3. Number of Histopathologically Detected Lesions Classified as Acute, Subacute, and Late Subacute
Animal Acute, <1 Week Subacute, 1–5 Weeks Late Subacute, 5–9 Weeks Total
WMH2 1 2 9 12
WMH3 1 2 2 3
WMH4 2 8 2 10
WMH5 1 2 3 6
Total 5 14 12 31
TABLE 2. Nondemyelinated Inflammatory Nodules Detected on Histopathology
Animal Nodule Nodule
Diameter,
lm
Distance from
Closest MRI
Visible Lesion,
lm
Number of
Perivascular
MRP14,
Degree of
Staining
Number of
Parenchymal
MRP14,
Degree of
Staining
Visible on
Ex Vivo
MRI
WMH3 1 206 4,741 3 (11) 1
2 227 651 2 2 2
WMH4 1 181 1,019 1 (1) 2 2
2 131 940 1 (1) 2 (1) 2
3 145 1,942 1 (11); 4 (1) 2 1
WMH5 1 115 2,515 2 2 2
2 225 1,830 2 2 2
3 148 7,080 2 (111) 2 2
4 103 497 2 2 2
All distance measurements were performed on the Iba1–stained sections, which identify microglia and macrophages. MRP14 stain-
ing, identifying blood-derived early activated macrophages, was measured as weak (1), moderate (11), or strong (111). The
rightmost column reports whether the lesion was visible (1) or not (2) on the high-resolution ex vivo MRI.
MRI5magnetic resonance imaging; Iba1 = ionized calcium binding adapter molecule-1; MRP145 calprotectin-monocyte L1 pro-
tein Ab-1.
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FIGURE 5: Representative magnetic resonance imaging (MRI) and histopathological features of acute lesions. (A, C) Acute lesions,
visible on the hematoxylin and eosin (H&E) section (blue arrow), were first seen on the terminal MRI (red arrow), performed on the
day the experiment ended. The time of lesion appearance on MRI is denoted tlesion50 and is measured in weeks, and these 2
lesions therefore appeared at most 1 week prior to the end of the experiment (lesion age<1 week). Red boxes indicate magnified
views. Scale bars5300lm. (B, D) Histopathological features of the acute lesions shown in A and C, respectively. Blood-derived
MRP141 early activated macrophages are present in the parenchyma but rarely within the perivascular space of the central blood
vessel. Iba11 activated microglia and macrophages are present in both parenchyma and perivascular space. GFAP1 astrocytes are
found in contact with the central vessel (B) and throughout the lesion (D). CD31 lymphocytes (T cells) are located in the perivascu-
lar space of the central vessel and sparingly in the adjacent parenchyma. CD201 lymphocytes (B cells) are located in the perivascu-
lar space of the central vessel and also in the parenchyma. CNPase1 oligodendrocytes and myelin are diminished in the lesion
parenchyma relative to surrounding white matter. Luxol fast blue (LFB) stains myelin in blue and demonstrates that the lesions are
demyelinated. Bielschowsky stain (Biels) shows axons that are disrupted and separated by inflammatory cells (red arrows), unlike
the tightly apposed axons in the adjacent parenchyma (white arrows). White boxes indicate magnified views. Scale bars5100 lm.
Animals: WMH4 (A, B); WMH3 (C, D).
FIGURE 6: Representative magnetic resonance imaging (MRI) and histopathological features of subacute lesions. (A, C) The
lesion (red arrows) is not visible on the preimmunization baseline scan (black arrows). The time of lesion appearance on MRI is
denoted tlesion50 and is measured in weeks. At the end of the experiment (Terminal T2PD MRI), the lesion in A was 1 to 3
weeks old and the lesion in C was 3 to 5 weeks old. Both lesions enlarged in the weeks after they appeared. A blood vessel
within the center of the lesion in A appears dark on MRI. The lesions are denoted by blue arrows on the hematoxylin and eosin
(H&E) sections. Red boxes indicate magnified views. Scale bars5300lm. (B, D) Histopathological features of the subacute
lesions shown in A and C, respectively. Blood-derived MRP141 early activated macrophages are present at the lesion edge.
Iba11 activated microglia and macrophages are found throughout the lesion, without a clear distinction between center and
periphery. Activated GFAP1 astrocytes are found within the lesion parenchyma and particularly in contact with blood vessels.
CD31 lymphocytes (T cells) are present in perivascular spaces and scattered throughout the lesion area. CD201 lymphocytes (B
cells) are only rarely present in parenchyma and perivascular spaces. CNPase1 oligodendrocytes and myelin are reduced in the
lesion parenchyma. Luxol fast blue (LFB), which stains myelin blue, shows complete myelin loss at the center and milder demye-
lination at the lesion margins. Bielschowsky stain (Biels) shows that normal axonal orientation and distribution are disrupted by
infiltrating inflammatory cells with regions of complete axonal loss and fragmentation. White boxes indicate magnified views.
Dark lines and arcs in various histopathological sections are folding artifacts. Scale bars5200 lm in B and 300 lm in D. Ani-
mals: WMH4 (A, B); WMH3 (C, D).
reduced at the lesion center relative to the margin.
Blood-derived MRP141 early activated macrophages
were distributed predominantly at the lesion edge. Iba11
activated microglia and macrophages were prominent
within both parenchyma and perivascular spaces and
were typically distributed throughout the entire lesion
area, without clear distinction between center and periph-
ery. Perivascular and parenchymal infiltrates of lympho-
cytes, most commonly CD31 T cells, were scattered
throughout the plaque. Astrocytes, important compo-
nents of the BBB, showed increased expression of GFAP
and thickened processes, suggesting activation, around
vasculature and throughout the lesion parenchyma. The
Bielschowsky stain showed that axons were disrupted and
separated by inflammatory cells, unlike axons in the
surrounding parenchyma, and also highlighted the pres-
ence of clear spaces (spongiosis) within the lesion and
surrounding parenchyma (evidence of myelin loss; see
Fig 6B, D).
Late Subacute Lesions
Late subacute lesions appeared on T2PD as small foci of
residual hyperintensity. These lesions were typically
shrinking over time on serial MRI, following a peak size
that was usually reached 1 to 3 weeks following lesion
appearance (Fig 7). All sampled late subacute lesions
came from animals WMH2 and WMH5 and showed
demyelination on LFB. Myelin at the lesion borders was
pale, a pattern that in MS has been correlated with
remyelination (shadow plaques). CNPase expression was
markedly reduced in the central lesion area, where LFB
depicted myelin loss, but close to normal in areas that
appeared pale on LFB. Blood-derived MRP141 early
activated macrophages were completely absent in 11 of
the 12 late subacute lesions (92%), but 1 lesion featured
a few perivascular and parenchymal MRP141 cells (<10
cells in total). In some of the younger late subacute
lesions, Iba11 activated microglia and macrophages were
present perivascularly and in the parenchyma, but in
older lesions they were more rare. A few CD31 T cells
and CD201 B cells were still present, mostly perivascu-
larly. Moderate numbers of GFAP1 astrocytes were seen
in the immediate perivascular area. Axons were mildly
disrupted by the presence of inflammatory cells.
Discussion
The major new finding in this study is that the BBB
becomes focally and increasingly permeable starting up
to 1 month before the appearance of new inflammatory,
demyelinating lesions in a primate model that recapitu-
lates immunopathogenic mechanisms of tissue damage in
relapsing–remitting MS. These permeability changes cor-
respond histopathologically to nondemyelinated inflam-
matory nodules comprising perivascular inflammation
and microglial activation without associated visible
abnormalities on MRI. MRI-visible lesions, conversely,
all featured clear demyelination. Myelin removal appears
to require the influx of MRP141 early activated macro-
phages from the blood, highlighting the importance of
the innate immune system in this process. However, our
data also suggest a key role for adaptive immunity during
the earliest stages of lesion formation, as evidenced by
the presence of lymphocytes in the perivascular cuff. The
sequence of events described in our data, and the relative
localization of the different cell populations at different
time points, together suggest that local inflammation
and, in our view, myelin damage, seem most likely to
result from the release of soluble, inflammatory, cytotoxic
factors as part of antigen-specific immune responses
within the perivascular cuff. Accordingly, lymphocytes
appear to be absent from the parenchyma prior to the
onset of demyelination.
The histopathological architecture of the nonde-
myelinated inflammatory nodules closely resembles foci
described in MS tissue samples,32 which have been
termed prephagocytic or predemyelinating.13,33 Because the
MS tissue samples derive from autopsies, however, they
cannot be definitively demonstrated to be the forerunners
of focal lesions. Conversely, in our marmoset EAE
experiments, weekly MRI scans allowed us to chart the
time course of BBB permeability changes within the
inflammatory nodules as well as in areas that eventually
evolved into demyelinated lesions, as seen both in vivo
(by MRI) and postmortem. The similar time courses
(indistinguishable rates of increase) and absent BBB
opening in corresponding areas of NAWM bolster our
contention that inflammatory nodules are the forerunners
of full-fledged demyelination. The data suggest, consist-
ent with some prior descriptions,34 that demyelination is
not the earliest event in the development of a plaque.
Conversely, microglial activation is prominent, as evi-
denced here by the presence of parenchymal cells that are
Iba11 but not MRP141.
Marmoset EAE lesions classified as acute in this
study closely resembled the “phagocytic areas” described in
MS histopathology studies.13 Their appearance on MRI
coincides with markedly elevated BBB permeability,
detected as increased DR1, which on conventional MRI
scans would correspond to visible contrast enhancement—
a prevalent finding in new MS lesions.9 Evaluation of these
acute lesions showed that blood-derived MRP141 early
activated macrophage infiltration is a good marker of the
leading edge of demyelination, whereas Iba1, which is
expressed in activated and resting microglia as well as
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FIGURE 7: Representative magnetic resonance imaging (MRI) and histopathological features of late subacute lesions (animal
WMH2). (A, C) Lesions (red arrows) are not visible on the preimmunization baseline scans (black arrows) but appeared >5
weeks before the end of the experiment. The lesion in A was between 6 and 8 weeks old, and the lesion in B was between 5
and 6 weeks old. Lesion size peaked in the weeks following lesion appearance but gradually diminished thereafter. Red boxes
indicate magnified views. Scale bars5300lm. (B) Histopathological features of the late subacute lesion shown in A. Blood-
derived MRP141 early activated macrophages are no longer seen. Iba11 activated microglia and macrophages remain perivasc-
ularly and in the parenchyma close to the central vessel. Astrocytes show moderate GFAP expression. CD31 (T cells) and
CD201 (B cells) lymphocytes are still present, although rare, in the parenchyma and perivascular spaces. CNPase1 oligodendro-
cytes and myelin are almost normal, except in the area immediately surrounding the central blood vessel. Luxol fast blue (LFB),
which stains myelin blue, shows pale myelin in the residual lesion area close to the central blood vessel, suggesting remyelina-
tion. Axons are mildly disrupted by inflammatory cell infiltrate with evidence of dissolution in comparison with surrounding,
closely packed axons. White boxes indicate magnified view. Scale bars5100lm. (D) Histopathological features of the late sub-
acute lesion shown in C. LFB shows absent myelin in the center of the lesion and pale myelin at the lesion margins. CNPase
expression is reduced at the lesion center but still partially present at the periphery. Iba11 activated microglia and macro-
phages are rarely present in the lesion area, but MRP141 macrophages are absent. CD31 lymphocytes (T cells) line the vessel
wall and persist throughout the lesion and in the perivascular spaces. Scale bars5100lm. Biels5Bielschowsky stain.
macrophages,22,35 is more diffusely distributed. MRP14 is
a calcium-binding protein that is found in neutrophils,
blood monocytes, and early activated infiltrating macro-
phages,23,36 although it is unclear whether this protein can
also be expressed, under certain conditions, in central nerv-
ous system–resident microglia.37 Based on previous litera-
ture on MS lesions, in which MRP14 expression has been
associated with the earliest stages of macrophage-mediated
demyelination,13,23,33,37,38 we speculate that in the acute
and subacute lesions observed here, MRP141 cells were
newly recruited, blood-derived monocytes and macro-
phages that were infiltrating the lesion parenchyma. The
radial spread of these cells mirrors the centrifugal spread of
intravenously injected contrast in the newest MS
lesions.30,39,40
Subacute lesions—1 to 5 weeks old at the time of post-
mortem examination—continued to enlarge over time even
as BBB permeability decreased. Considering that BBB perme-
ability was measured in the central area of the lesion (an area
corresponding to the lesion size in its acute stage), this finding
is consistent with recent data in newly forming MS lesions,
where the locus of BBB opening moves outward with time
from the central blood vessel to the periphery of the expand-
ing plaque.30 In subacute EAE lesions, active demyelination
was only present at the lesion edge, having completed in the
lesion center around the central vessel. Blood-derived
MRP141 early activated macrophages were found at the lead-
ing edge of demyelination, whereas Iba11 cells (at this stage
presumably a combination of microglia and macrophages)
were diffusely distributed. Conversely, in late subacute lesions
>5 weeks old, inflammation was markedly reduced. Demye-
lination and its attendant MRP141 infiltration were absent,
and there was some evidence of pale myelin staining with
LFB, which could reflect nascent remyelination. Late subacute
lesions generally became smaller over time, a finding that is
consistent with an overall reduction of inflammation in older
lesions, as has been described in MS.22
The data presented here, in conjunction with litera-
ture reports from previous studies, allow us to construct a
model of white matter lesion formation in marmoset EAE,
which is also consistent with what is known about this pro-
cess in MS (Fig 8). Based on our imaging and histopatho-
logical data, we believe that the nondemyelinated
inflammatory nodules are the earliest cellular manifesta-
tion of lesion formation. These nodules are perivascular
collections of lymphocytes and Iba11 perivascular macro-
phages, together with parenchymal microglia, reactive
astrocytes, and normal myelin. This finding is consistent
with the migration of peripherally primed, myelin-reactive
T cells into the perivascular space either from the cerebro-
spinal fluid compartment,41 perhaps via the choroid
plexus,42 or directly across the endothelium.43 In the peri-
vascular space, these T cells encounter myelin antigens that
reach this space and are presented by perivascular macro-
phages.44,45 Activation of these T cells following antigen
presentation leads to secretion of cytokines and chemo-
kines,33 which in turn activate both vascular endothelium
and resident microglia,46 in agreement with previous find-
ings in prephagocytic/predemyelinating lesions in MS.15
The MRI correlate of these processes is increased perme-
ability to injected contrast material, corresponding to
subtle opening of the endothelial side of the BBB. Within
a few weeks, the parenchymal side of the BBB (also known
as the glia limitans) is breached, and demyelination com-
mences. Blood-derived MRP141 macrophages arrive to
strip the damaged, perhaps complement-coated, mye-
lin.33,46 At this stage, Iba11 microglia within the lesion
FIGURE 8: Model of lesion formation in marmoset experi-
mental autoimmune encephalomyelitis. Peripherally primed
myelin-reactive T cells (CD31 T cells) pass into the perivas-
cular space and recognize myelin antigens on the surface of
antigen-presenting cells (eg, Iba11 perivascular macro-
phages). Activation of these T cells following antigen pre-
sentation then activates both the vascular endothelium
(leading to subtle blood–brain barrier opening) and resident
microglia (Iba11 microglial activation) by secreting soluble
factors (cytokines and chemokines). These inflammatory fac-
tors enter the parenchyma, initiating tissue damage (includ-
ing myelin damage) and activating resident microglia.
Within a few weeks, the parenchymal side of the blood–
brain barrier (the glia limitans) is breached, and early acti-
vated macrophages (blood-derived MRP141 cells) infiltrate
the parenchyma to remove myelin.
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may have multiple roles, including possibly repair.35 After
a period lasting almost 5 weeks, the inflammatory activity
of the lesion decreases, MRP141 cells disappear, and
remyelination commences.
Although this model is consistent with data from our
serial MRI scans and postmortem histopathology, we did not
perform an exhaustive cellular, molecular, and biochemical
analysis of the specific mechanisms by which tissue damage
(demyelination and axonal loss) develops from inflammatory
nodules. Future studies along these lines would benefit from
a histological marker of oligodendrocyte apoptosis suitable
for marmoset tissues. Such studies could also examine the
effects of selective blockade of blood-derived macrophage
infiltration, providing further insight into the extent to which
those cells are required for demyelination to occur.
Finally, thanks to the strong immunological and
histopathological similarities between the marmoset EAE
model and the human disease, we believe that our find-
ings may have important translational value with respect
to MS. The precise sequencing of tissue changes enabled
by the imaging–pathology correlations reported here may
improve the targeting of new therapies that address vari-
ous stages of the process, helping to elucidate their mech-
anisms of action.
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